Skip to main content
. 2016 Jul 14;6:29736. doi: 10.1038/srep29736

Figure 2. Upregulation of B cell markers in primary and metastatic melanomas compared with normal skins by gene expression analysis.

Figure 2

(a) The relative expression of genes for the humoral immune markers CD20, CD22 and AID are elevated in primary and metastatic lesions compared with normal skin samples and also elevated in metastatic versus primary melanomas (n = 234, normalized microarray gene expression data from indicated studies, GEO database; One-way ANOVA with Tukey’s post hoc test). (b) Increased CD20, CD22, and AID relative expression in primary versus metastatic melanomas (n = 384, TCGA database; T-test with Welch’s correction was performed). (a,b) Graphs show mean ± SEM gene expression, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (c) Kaplan-Meier estimates of overall survival in TCGA melanoma patients according to CD20, CD22 and AID mRNA expression. Gene expression was categorized as low and high expression according to the median expression value and differences were compared using the log-rank test. High CD20 expression was significantly associated with better survival (n = 384; Hazard ratio (HR):1.82; 95% confidence interval (CI):1.36–2.43; p < 0.001). Detailed statistical analyses are described in Materials and Methods.